279 related articles for article (PubMed ID: 20606045)
21. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
Yang DT; Young KH; Kahl BS; Markovina S; Miyamoto S
Mol Cancer; 2008 May; 7():40. PubMed ID: 18489772
[TBL] [Abstract][Full Text] [Related]
22. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
Alinari L; White VL; Earl CT; Ryan TP; Johnston JS; Dalton JT; Ferketich AK; Lai R; Lucas DM; Porcu P; Blum KA; Byrd JC; Baiocchi RA
MAbs; 2009; 1(1):31-40. PubMed ID: 20046572
[TBL] [Abstract][Full Text] [Related]
23. Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways.
Rizzatti EG; Mora-Jensen H; Weniger MA; Gibellini F; Lee E; Daibata M; Lai R; Wiestner A
Leuk Lymphoma; 2008 Apr; 49(4):798-808. PubMed ID: 18398749
[TBL] [Abstract][Full Text] [Related]
24. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
Kim A; Park S; Lee JE; Jang WS; Lee SJ; Kang HJ; Lee SS
Leuk Res; 2012 Jul; 36(7):912-20. PubMed ID: 22560334
[TBL] [Abstract][Full Text] [Related]
25. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
Bhalla S; Balasubramanian S; David K; Sirisawad M; Buggy J; Mauro L; Prachand S; Miller R; Gordon LI; Evens AM
Clin Cancer Res; 2009 May; 15(10):3354-65. PubMed ID: 19417023
[TBL] [Abstract][Full Text] [Related]
26. Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.
Cagnetta A; Cea M; Calimeri T; Acharya C; Fulciniti M; Tai YT; Hideshima T; Chauhan D; Zhong MY; Patrone F; Nencioni A; Gobbi M; Richardson P; Munshi N; Anderson KC
Blood; 2013 Aug; 122(7):1243-55. PubMed ID: 23823317
[TBL] [Abstract][Full Text] [Related]
27. Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation.
Cowan AJ; Frayo SL; Press OW; Palanca-Wessels MC; Pagel JM; Green DJ; Gopal AK
Anticancer Drugs; 2015 Oct; 26(9):974-83. PubMed ID: 26237500
[TBL] [Abstract][Full Text] [Related]
28. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.
Pérez-Galán P; Roué G; Villamor N; Montserrat E; Campo E; Colomer D
Blood; 2006 Jan; 107(1):257-64. PubMed ID: 16166592
[TBL] [Abstract][Full Text] [Related]
29. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN
Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443
[TBL] [Abstract][Full Text] [Related]
30. The STAT3 inhibitor WP1066 synergizes with vorinostat to induce apoptosis of mantle cell lymphoma cells.
Lu K; Chen N; Zhou XX; Ge XL; Feng LL; Li PP; Li XY; Geng LY; Wang X
Biochem Biophys Res Commun; 2015 Aug; 464(1):292-8. PubMed ID: 26116769
[TBL] [Abstract][Full Text] [Related]
31. Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach.
Chaturvedi NK; Rajule RN; Shukla A; Radhakrishnan P; Todd GL; Natarajan A; Vose JM; Joshi SS
Mol Cancer Ther; 2013 Oct; 12(10):2006-17. PubMed ID: 23963361
[TBL] [Abstract][Full Text] [Related]
32. Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma.
Jung HJ; Chen Z; Fayad L; Wang M; Romaguera J; Kwak LW; McCarty N
Exp Hematol; 2012 Feb; 40(2):107-18.e2. PubMed ID: 22024108
[TBL] [Abstract][Full Text] [Related]
33. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
34. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
[TBL] [Abstract][Full Text] [Related]
35. The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner.
Martin SM; Churchill E; McKnight H; Mahaffey CM; Ma Y; O'Donnell RT; Tuscano JM
J Hematol Oncol; 2011 Dec; 4():49. PubMed ID: 22128838
[TBL] [Abstract][Full Text] [Related]
36. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
Leonard JP; Furman RR; Coleman M
Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
[TBL] [Abstract][Full Text] [Related]
37. Combined administration of rituximab and on 013105 induces apoptosis in mantle cell lymphoma cells and reduces tumor burden in a mouse model of mantle cell lymphoma.
Prasad A; Shrivastava A; Papadopoulos E; Kuzontkoski PM; Reddy MV; Gillum AM; Kumar R; Reddy EP; Groopman JE
Clin Cancer Res; 2013 Jan; 19(1):85-95. PubMed ID: 23124440
[TBL] [Abstract][Full Text] [Related]
38. Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA.
Heine S; Kleih M; Giménez N; Böpple K; Ott G; Colomer D; Aulitzky WE; van der Kuip H; Silkenstedt E
J Hematol Oncol; 2018 Sep; 11(1):112. PubMed ID: 30180865
[TBL] [Abstract][Full Text] [Related]
39. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model.
Sung B; Kunnumakkara AB; Sethi G; Anand P; Guha S; Aggarwal BB
Mol Cancer Ther; 2009 Apr; 8(4):959-70. PubMed ID: 19372569
[TBL] [Abstract][Full Text] [Related]
40. N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products.
Shishodia S; Gutierrez AM; Lotan R; Aggarwal BB
Cancer Res; 2005 Oct; 65(20):9555-65. PubMed ID: 16230421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
